- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04547452
Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC
Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a common malignancy, and more than 70% of newly diagnosed HCC patients already have advanced disease. Sorafenib and lenvatinib are recommended as first-line options for advanced HCC. The PD-1 monoclonal antibody,such as nivolumab and pembrolizumab, have been approved to treat the patients with advanced HCC by the FDA. Combining radiotherapy with immune checkpoints showed promising response rates and improved survival in several solid tumor types. The purpose of this randomized study is to determine whether stereotactic body radiation therapy (SBRT) combined with sintilimab (an anti-PD-1 antibody) will improve the response to the anticancer treatment compared to sintilimab alone in patients with advanced HCC.
About 84 participants will be enrolled in this study. All will take part at West China Hospital, Sichuan University.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A total of 84 HCC patients who are failure from the first line Sorafenib or lenvatinib treatment will be randomized to two treatment arms using a 1:1 ratio: SBRT + PD-1 arm or PD-1 alone arm.
Patients in both arms will receive sintilimab administered intravenously at 200 mg every 3 weeks. Stereotactic body radiotherapy (SBRT) using volumetric arc therapy. The prescribed dose is 30-54 Gy in 3-6 fractions over 1-2 weeks. In the SBRT + PD-1 arm, sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. The first course of sintilimab will be given within 4-6 weeks after completion of SBRT.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jitao Zhou, PhD/MD
- Phone Number: +86 28 85423609
- Email: zjthelen@sina.com
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- West China Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically confirmed hepatocellular carcinoma or diagnosed by American Association for the Study of Liver Disease criteria;
- Deemed ineligible for curative intent therapy with surgical resection or liver transplantation.
- Estimated life expectancy ≥12 weeks;
- Male or female subjects with age: 18-70 years old
- Failure in first-line systemic treatment with sorafenib or Lenvatinib
- Unwilling to receive or unable to tolerate first-line treatment with sorafenib
- Have ECOG performance status 0-1
- Have measurable disease based on RECIST 1.1.
- Pretreatment CT chest /abdomen /pelvis within 28 days of protocol enrollment.
- Child-Pugh class A liver function (assessed within 14 days of SBRT);
- The function of important organs meets the following requirements: a. white blood cell count (WBC) ≥ 3.0×109/L, absolute neutrophil count (ANC) ≥ 1.5×109/L; b. platelets ≥ 50×109/L; c. hemoglobin ≥ 8g/dL; d. serum albumin ≥ 3.0g/dL; e. total bilirubin ≤ 2.0×ULN, ALT, AST ≤ 5×ULN; f. serum creatinine ≤ 1.5×ULN
- Must have at least one lesion amenable to SBRT.
- Ability to understand the study and sign informed consent.
Exclusion Criteria:
- A history of abdominal radiotherapy;
- Presence of active hepatitis B (HBV DNA ≥ 2000 IU/mL or 104 copies/mL), hepatitis C (positive for hepatitis C antibody, and HCV-RNA levels higher than the lower limit of the assay);
- Active autoimmune diseases, a history of autoimmune diseases (including but not limited to these diseases or syndromes, such as colitis, hepatitis, hyperthyroidism), a history of immunodeficiency (including a positive HIV test result)
- History of organ transplantation or allogeneic bone marrow transplantation,or other acquired or congenital immunodeficiency diseases
- Receipt of live, attenuated vaccine within 30 days prior to the study treatment
- Has a known history of active TB (Bacillus Tuberculosis).
- Uncontrolled intercurrent illness including, but not limited to digestive tract ulcer, uncontrolled hypertension, fracture, uncured wound, history of congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Prior invasive malignancy within 2 years except for noninvasive malignancies such as cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, lobular or ductal carcinoma in situ of the breast that has been surgically cured
- Female patients who are pregnant or lactating
- Untreated central nervous system (CNS) metastatic disease, lepto-meningeal disease, or cord compression
- Active infection requiring systemic therapy
- Presence of clinically meaningful ascites,hydrothorax or hydropericardium and patients requiring non pharmacologic intervention (eg, paracentesis) or escalation in pharmacologic intervention to maintain symptomatic control
- Severe hypersensitivity reaction to treatment with another monoclonal antibody (mAb)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sintilimab Combined with SBRT
Patients will be randomly placed in either of the two arms. Participants enrolled in this arm treated to a total dose of 35-80Gy in 5-8 fractions with stereotactic radiotherapy to a liver or lung or any metastatic lesion. The choice of radiation dose will be at the discretion of the treating radiation oncologist. Sintilimab is administered intravenously at 200 mg every 3 weeks for up to 1 year. |
Sintilimab Combined with SBRT
Other Names:
Sintilimab
|
Active Comparator: Sintilimab
Participants enrolled in this arm treated with sintilimab administered intravenously at 200 mg every 3 weeks for up to 1 year.
|
Sintilimab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
24-week progression-free survival (PFS) ratev
Time Frame: 24 weeks after radiotherapy
|
The proportion of patients with progression disease according to mRECIST at 24 weeks from randomization.
|
24 weeks after radiotherapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: up to 24 months after the enrollment
|
Investigator assessed ORR using RECIST v1.1 including the all tumor, the tumor undergoing LDRT and the tumor which do not receive radiotherapy.
|
up to 24 months after the enrollment
|
Overall Survival (OS)
Time Frame: up to 24 months after the enrollment
|
OS is defined as the difference (in months) between the date of study enrollment to the date death due to any cause
|
up to 24 months after the enrollment
|
24-week disease control rate (DCR)
Time Frame: 24 weeks after radiotherapy
|
The proportion of patients with complete response, partial response or stable disease according to mRECIST at 24 weeks from randomization.
|
24 weeks after radiotherapy
|
Duration of response (DOR)
Time Frame: up to 24 months after the enrollment
|
From date of first CR/PR to the date of first PD according to RECIST criteria, assessed up to 24 months.
|
up to 24 months after the enrollment
|
Adverse Events
Time Frame: 2 years from randomization
|
Treatment-related adverse events are graded according to the Common Toxicity Criteria, version 4.0, and were registered from the date of informed consent until discontinuation of trial treatment.
|
2 years from randomization
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- I-SBRT-HCC-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immunotherapy
-
Ajou University School of MedicineCompletedImmunotherapyKorea, Republic of
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
Centre Georges Francois LeclercAstraZenecaActive, not recruiting
-
Power Life Sciences Inc.Not yet recruitingCancer | Immunotherapy
-
Xuanwu Hospital, BeijingRecruitingImmunotherapy | ADRChina
-
Rutgers, The State University of New JerseyPfizer; American Cancer Society, Inc.CompletedImmunotherapy | Clinical TrialsUnited States
-
Peking University First HospitalYiZhou International Cancer HospitalUnknownImmunotherapy | Proton Therapy
-
Nanfang Hospital, Southern Medical UniversityRecruitingImmunotherapy | Biomarker | HyperprogressionChina
-
Peking University First HospitalNot yet recruitingImmunotherapy | SBRT | Bulky Tumor
Clinical Trials on Stereotactic body radiation therapy
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Cancer Prevention Research Institute of TexasActive, not recruitingMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Malignant Neoplasms of Urinary Tract | Oligometastatic Renal Cell CarcinomaUnited States
-
Roswell Park Cancer InstituteCompletedLung CancerUnited States
-
University of Texas Southwestern Medical CenterCompletedPain | Unspecified Adult Solid Tumor, Protocol Specific | Metastatic CancerUnited States
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyCompletedLung CancerUnited States, Canada
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Prostate AdenocarcinomaUnited States, Canada, Hong Kong, Switzerland, India, Ireland
-
Barts & The London NHS TrustBarts Cardiovascular CTU (Queen Mary University of London)Not yet recruitingHypertrophic CardiomyopathyUnited Kingdom
-
Erasmus Medical CenterCompletedKlatskin TumorNetherlands
-
Paul W. Read, MDUnknownMetastatic Bone LesionUnited States
-
University of FloridaCompletedSpinal TumorsUnited States
-
Peking University Third HospitalRecruitingThoracic Cancer | Radiotherapy | Safety and EfficacyChina